CS-206

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameCS-206

Drug Alias NameAutologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique therapy (Children’S Hospital Of Fudan University)CS-206

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing > Base editing

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsAnemia, Sickle Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesChildren’S Hospital Of Fudan University

China Registration ClassN/A

Develop Information

Active CompaniesChildren’S Hospital Of Fudan University

Inactive CompaniesN/A

Active IndicationsAnemia, Sickle Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A